NCT04738045 is a Phase 4 clinical trial of Remdesivir in Covid19, sponsored by Ahmed Essam.

Who is sponsoring NCT04738045?

NCT04738045 is sponsored by Ahmed Essam.

What drugs are being tested in NCT04738045?

Interventions in NCT04738045: Remdesivir, Lopinavir/ Ritonavir and Remdesivir combination.

Is NCT04738045 still recruiting?

NCT04738045 is currently status unknown. Last updated 17 March 2021.

Last reviewed 2021-03-17 · How we verify

NCT04738045

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients

Status unknown Phase 4 Last updated 17 March 2021

What this trial tests

Phase 4 trial testing Remdesivir in Covid19 in 90 participants. Status unknown.

Timeline

1 November 2020

Primary endpoint
28 March 2021

1 April 2021

Quick facts

Lead sponsor	Ahmed Essam
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	1 November 2020
Primary completion	28 March 2021
Estimated completion	1 April 2021
Sites	1 location across Egypt

Drugs / interventions tested

Remdesivir (remdesivir) — full drug profile →
Lopinavir/ Ritonavir and Remdesivir combination — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Ahmed Essam — full company profile →

Who can join

Adults 18 to 80, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparison outcomes of a large cohort of moderate and severe COVID-19 patients received remdesivir alone with patients who received remdesivir in combination with lopinavir/ ritonavir in addition to standard management.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.
Sun C, Xie C, Bu GL, Zhong LY, et al · · 2022 · cited 90× · PMID 35764603 · DOI 10.1038/s41392-022-01039-2
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
Ning Q, Wu D, Wang X, Xi D, et al · · 2022 · cited 64× · PMID 35197452 · DOI 10.1038/s41392-022-00907-1
The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy.
Kouhpayeh S, Shariati L, Boshtam M, Rahimmanesh I, et al · · 2021 · cited 26× · PMID 34064039 · DOI 10.3390/ijms22115438
Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection.
Akbarzadeh-Khiavi M, Torabi M, Rahbarnia L, Safary A. · · 2022 · cited 21× · PMID 34902115 · DOI 10.1007/s15010-021-01730-6
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective.
Pozzi C, Vanet A, Francesconi V, Tagliazucchi L, et al · · 2023 · cited 19× · PMID 36857133 · DOI 10.1021/acs.jmedchem.2c01229
Existing Drugs Considered as Promising in COVID-19 Therapy.
Janik E, Niemcewicz M, Podogrocki M, Saluk-Bijak J, et al · · 2021 · cited 19× · PMID 34063964 · DOI 10.3390/ijms22115434
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
Negru PA, Radu AF, Vesa CM, Behl T, et al · · 2022 · cited 18× · PMID 35131656 · DOI 10.1016/j.biopha.2022.112700

Verify or expand the search:

Other trials of Remdesivir

Trials testing the same drug.

NCT06817889 — Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals · Phase 2 · recruiting
NCT05911906 — An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. · Phase 4 · completed
NCT06860282 — A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects · Phase 1 · completed
NCT05502081 — Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hos · Phase 4 · completed
NCT05780541 — PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) · Phase 3 · terminated

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04738045 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ahmed Essam
Last refreshed: 17 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04738045.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing